Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Policy Watch: FDA Looks to Expand Real-Time Drug Clinical Trials
The FDA has launched an AI‑driven pilot that streams clinical‑trial data in real time for AstraZeneca and Amgen’s lymphoma and lung‑cancer studies, and is now seeking public input to broaden the approach. The Ninth Circuit Court declined to compel the EPA to act on a petition to ban organophosphate pesticides, noting a four‑year delay falls short of an unreasonable standard and allowing the agency to wait until the 2026 registration‑review deadline. A separate FDA study of 312 infant‑formula samples found most contaminants well below EPA drinking‑water limits, with only a minority exceeding thresholds for heavy metals and phthalates. Together, these stories highlight how regulators are balancing speed, safety, and public scrutiny across drug approval, pesticide oversight, and food safety.
Gut Microbe’s Sulfated Bile Acid Eases Pediatric Sepsis
Researchers identified deoxycholic acid 3‑sulfate (DCA‑3S) as a gut‑derived metabolite that mitigates pediatric sepsis. Metabolomic and metagenomic analyses revealed Enterococcus raffinosus as the primary producer, accounting for over 80 % of DCA‑3S synthesis. In mouse models, DCA‑3S restored intestinal barrier integrity and dampened...
STAT+: Axsome Wins FDA Nod for Alzheimer’s Agitation
Axsome Therapeutics announced that the U.S. Food and Drug Administration has granted a regulatory nod for its investigational therapy aimed at treating agitation in Alzheimer’s disease. The agency’s decision clears the path for accelerated clinical development, potentially moving the drug...
How Medicare Blocks Access to Lifesaving Treatments
Medicare’s Coverage with Evidence Development (CED) policy has limited access to transcatheter aortic valve replacement (TAVR), a minimally invasive heart‑valve procedure, for millions of seniors with severe aortic stenosis. Although TAVR became the clinical standard of care by 2017, Medicare...
Novel Pulsed Field Ablation Technology ‘Works’
A first‑in‑human trial of Pulse Biosciences' nanosecond pulsed‑field ablation (CellFX nsPFA 360) treated 177 patients with paroxysmal atrial fibrillation. The catheter delivered >10,000 V nanosecond pulses, achieving 100% acute lesion success and 91% durability at 2‑3 months. At one year, 89.7% of patients remained free...
Re: GMC: Doctors to Get New Rules on Their Personal Beliefs and Work
The General Medical Council (GMC) is set to introduce new rules governing how doctors may invoke personal beliefs in clinical practice. The proposal clarifies that conscientious objection is permissible only when it does not lead to discrimination or denial of...
The Multimodal Explosion: Why 2026 Breaks the AI Paradigm
In 2026 AI transitions from isolated tools to multimodal platforms that fuse transcripts, labs, notes, and device data, closing the "Synthesis Gap" in clinical workflows. This integration enables "minimal‑click" medicine, surfacing critical information in real time and freeing clinicians to...
AI: Are Psychiatric Times, MJH Life Sciences the Past or Future of Psychiatry?
The article contends that Psychiatric Times, owned by MJH Life Sciences, has contributed little to neuroscience‑driven psychiatry despite four decades of publication, a shortcoming that becomes stark as AI mental‑health therapists gain traction. It argues that meaningful progress requires linking...
Peptides Are Unproven as Health Aids. FDA May Unleash Them Anyway
The FDA is poised to broaden access to injectable peptides by allowing compounding pharmacies to produce them and by considering their inclusion in oral dietary supplements. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly opposed what he...
Google's AI Co-Clinician Outperforms Docs in Telemedicine Exams
Did Google just show us the path to the Telemedicine AI Agent of the future? Meet Google’s “AI Co-Clinician” and my prediction for how this could all play out... First, what Google shared: → A fully AI telemedicine visit where the AI...
Drug Trials Snapshot: TRYNGOLZA
TRYNGOLZA (olezarsen), an APOC‑III‑directed antisense oligonucleotide, received FDA approval on December 19, 2024 for adults with familial chylomicronemia syndrome (FCS). In the pivotal Phase 3 trial (NCT04568434), 66 patients from 11 countries received monthly 80 mg injections or placebo for 53 weeks. The drug achieved...
A System Failing by Design: Lessons From Two Decades of Deferred Reform
The 2006 NHS dental contract, built around a unit‑of‑activity model, incentivises high‑volume, low‑prevention care, prompting a wave of conscientious dentists to leave the system. Practices are now returning roughly £900 million in NHS funding because the payment structure is financially unsustainable...
Programmable RNA Targeting via DNA-Guided CRISPR-Cas12a
A team of molecular biologists has reengineered the CRISPR‑Cas12a nuclease to cleave RNA using a DNA guide, creating a programmable RNA‑targeting platform. The DNA‑guided Cas12a system achieved up to 90% knockdown of endogenous transcripts in human cell lines and functioned...
Drug Trials Snapshot: ALYFTREK
Vertex Pharmaceuticals received FDA approval for ALYFTREK, a triple‑combination CFTR modulator, on Dec. 20, 2024. The drug targets cystic fibrosis patients aged six and older with at least one F508del or other responsive mutation. Approval was based on two 52‑week, non‑inferiority trials...
AI Telehealth Startup MEDVi Draws Scrutiny Over Marketing, Compliance
MEDVi, an AI‑powered telehealth startup specializing in weight‑loss drugs, has surged to hundreds of millions in revenue while operating with a minimal staff. On Feb. 20, 2026 the FDA issued a warning letter accusing the company of false and misleading claims about...
Direct-To-Consumer Drug Portals Offer Lower Prices, But Preserve Inequities
President Trump launched TrumpRx, a federal direct‑to‑consumer portal that sells dozens of prescription drugs at cash‑pay discounts. The program relies on confidential three‑year agreements with 17 manufacturers, using most‑favored‑nation pricing tied to nine wealthy nations. While the portal lowers out‑of‑pocket...
Drug Trials Snapshot: ROMVIMZA
Deciphera's ROMVIMZA (vimseltinib) received FDA approval on Feb 17 2025 for adult tenosynovial giant‑cell tumor (TGCT) when surgery is unsuitable. Approval was based on a global phase II trial of 123 patients, showing a 40% overall response rate versus 0% with placebo...
RFK Jr.’s Unsupported Claims About Tylenol-Autism Study He Called ‘Garbage’
During an April 17 congressional hearing, Health and Human Services Secretary Robert F. Kennedy Jr. demanded the retraction of a new Danish study that found no link between acetaminophen (Tylenol) and autism, calling the research “garbage” and alleging fraud. Scientists refuted his accusations, pointing...
Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman
Jeff Golfman, founder of Send 123, warned that rising geopolitical tensions—particularly around Iran and the Strait of Hormuz—are tightening global pharmaceutical and medical supply chains. Shipping bottlenecks and shrinking capacity are driving up prices and threatening access to critical therapies such...
WATCH NOW: Prior Authorization: Care, Delayed | EP 3
In this episode of Healthcare Uncovered, the hosts examine the burdens of prior authorization on patients and clinicians, featuring Dr. Wendy Dean, co‑founder of Moral Injury of Healthcare, and former health‑system executive Dr. Seth Glickman. They discuss how prior‑auth requirements...
Africa CDC Urges Continental Integration of Mental Health, NCDs Into Primary Care
At the World Health Summit in Nairobi, the Africa Centres for Disease Control and Prevention urged all African countries to integrate mental health, non‑communicable diseases and injury services into primary health care. The agency said the move is essential to...
Duke AI Tool Predicts ADHD Risk in Kids as Young as Five with 0.92 Accuracy
Duke University scientists released an artificial‑intelligence screening tool that can identify children at high risk for attention‑deficit/hyperactivity disorder as early as age five, achieving a time‑dependent AUC of 0.92. The model, built on electronic health records from more than 140,000...
Study Finds Postpartum Depression Peaks at 8.3% Two Weeks After Birth
University of Queensland researchers have released the largest mental‑health meta‑analysis to date, revealing that major depression reaches a peak of 8.3 % in the first two weeks after childbirth. The finding underscores a narrow window for early detection and intervention in...
The Fifty Billion Dollar Rural Health Wager
The CMS Rural Health Transformation Program (RHTP) will inject $50 billion over FY26‑30—$10 billion per year—into rural health, dividing each state’s allocation equally and merit‑based. RHTP sits atop a broader federal capital stack that includes HRSA grants, USDA loans, FCC broadband funds,...
Maine Launches Paid Family Leave, Offering Up to 12 Weeks of Wage Replacement
Maine’s paid family‑leave program went live on May 1, allowing employees to take up to 12 weeks of partially paid leave for childbirth, illness or caregiving. The state expects 22,000 workers to use the benefit this year, with projected payouts of...
Cerus Names Vivek K. Jayaraman as New COO, Raises 2026 Revenue Guidance
Cerus Corporation introduced Vivek K. Jayaraman as its incoming chief operating officer during its Q1 2026 earnings call. The leadership change coincides with a 24% jump in product revenue to $53.7 million and an upward revision of full‑year product revenue guidance...
Summit Slips on Ivonescimab's Apparent Interim Miss in Sign of Investor Frustration
Summit Therapeutics’ shares plunged almost 20% after an interim analysis of its Phase 3 trial of ivonescimab showed a statistical shortfall in a key efficacy endpoint. The miss was limited to a subgroup analysis, but investors interpreted it as a signal...
Labcorp CFO Julia Wang Highlights $71M Free Cash Flow and $202M Capital Deployment in Q1
Labcorp's chief financial officer Julia Wang detailed a $71 million free‑cash‑flow swing and $202 million of capital deployment in the first quarter, underscoring tighter expense management and a focus on high‑margin growth. The guidance for 2026 projects 5%‑6.1% enterprise‑revenue growth and adjusted...
TIME Names Xenco Medical One of the TIME100 Most Influential Companies in the World and the Winner of the 2026...
Xenco Medical was named one of the 2026 TIME100 Most Influential Companies and received the exclusive TIME100 Impact Award in Health. The accolade follows prior honors such as 2025 Medical Device/Diagnostics Company of the Year, Fast Company’s Most Innovative Companies,...
High‑dose Semaglutide Cuts Alcohol Use in RCT
Clinicians and patients saw big reductions in alcohol intake when starting GLP-1 medicine. This is the first randomized trial to look at the high dose of semaglutide. There was a study a couple years back looking at a lower dose....
T‑cell Vesicles Deliver DNA, Converting Cold Tumors Hot
In cancer, activated T cells release abundant extracellular vesicles that transfer DNA to the nucleus of tumor and immune (dendritic) cells, turning tumors from cold to hot. An immunotherapy in the works. @Cancer_Cell https://t.co/mHcahijOJC https://t.co/oPT6d7lrFM https://t.co/I0egYxZold
Empa and HOCH Health Launch Light‑Activated Nanozyme Therapy for Brain Tumors
Empa and the HOCH Health Ostschweiz network have begun a research partnership to create a light‑activated nanozyme therapy for astrocytoma and other aggressive brain tumors. The project, funded by several Swiss foundations, targets the blood‑brain barrier challenge and plans to...
Biotech IPOs Surge, Exposing Wall St Underestimation
Three biotech IPOs this week. Each one raised its number of shares and priced atop range. Suggests that Wall St is slightly underestimating investor interest in new biotech issues.
Demo Shows How Claims Data Powers Executive Decisions
I went to a conference. Healthcare payers one. Listened to talks about claims data … build a system over the weekend to demo how data can be used these days by execs (and obviously it’s not about reports 😂) comment...
Amgen Files Update to Tavneos Label as FDA Escalates Push to Withdraw
Amgen filed a supplemental application to revise the prescribing information for its rare‑disease drug Tavneos (avacopan) as the FDA intensifies its effort to withdraw the product. The label update seeks to add new safety warnings and monitoring requirements after the...
AI Chatbots Capture Poorer Symptom Detail than Doctors
Symptoms reported to an AI chatbot were of lesser quality than reported to a physician, results of a randomized trial of 500 participants across multiple models https://t.co/WXP4R3y9HA https://t.co/l2hLT76AJB
5 Questions to Consider When Choosing a Birth Control Method
Choosing a birth control method involves weighing hormonal versus non‑hormonal options, each with distinct efficacy rates ranging from 87% to 99% for typical use. The article outlines five key questions—effectiveness, daily management, medical compatibility, future fertility plans, and STI risk—to...
Getein Biotech Q1 Profit Rises 18% to $10.7M as Revenue Hits $37.5M
Getein Biotech posted a first‑quarter profit of RMB76.3 million ($10.7 M), up 18% year‑over‑year, and revenue of RMB267.5 million ($37.5 M), a 9.6% increase. The results highlight accelerating demand for molecular diagnostics in China.
AJMC® in the Press, May 1, 2026
The CDC paused diagnostic testing for mpox and rabies as part of a strategic laboratory downsizing, shifting initial confirmation duties to state and local public‑health labs. This change raises concerns about treatment delays, especially for post‑exposure prophylaxis. The pause was...
GoodRx Partners with Novo Nordisk to Offer Self-Pay Pricing for New Oral Ozempic® Pill
GoodRx has teamed with Novo Nordisk to sell the newly launched oral Ozempic® pill at transparent self‑pay rates, ranging from $149 to $299 per month depending on dosage. The tiered pricing covers the 1.5 mg, 4 mg and 9 mg strengths, letting patients...
If AI Replaces Radiologists, Who Owns The Outcome?
The article argues that AI will not replace radiologists; instead, it reshapes the responsibility chain in imaging care. While AI can accelerate detection and reduce workload, the radiologist’s role in communicating findings and ensuring follow‑up remains essential. The real challenge...
Peer Support and Case Management: Complementary, Not Interchangeable
The article clarifies that case managers and peer support specialists, while both essential in behavioral health, serve distinct functions and should not be used interchangeably. Case managers coordinate services, handle Medicaid, housing, and compliance, whereas peer specialists provide relational, lived‑experience...
Amgen Positions MariTide as Potential ‘Best Monthly’ Obesity Drug
Amgen is positioning its bispecific antibody‑peptide MariTide as the premier monthly or less‑frequent obesity treatment. The company launched a Phase 3 MARITIME‑Switch study to evaluate switching patients from weekly GLP‑1 injections to four‑to‑six monthly doses. Phase 2 data showed up to a...
Top Psychiatrists Call for a Greater Focus on Ceasing Medication
Health Secretary Robert F. Kennedy Jr. is pushing to curb psychiatric drug use, prompting leading psychiatrists to draft deprescribing guidance. The group, convened by the American Society of Clinical Psychopharmacology, released initial recommendations in JAMA Network Open and the British Journal...
Theradaptive Receives US FDA Approval to Initiate P-III Trial of OsteoAdapt SP for Spinal Fusion Procedures
Theradaptive has secured U.S. FDA approval to launch the pivotal OASIS Phase III trial evaluating its OsteoAdapt SP device as a bone‑graft alternative in transforaminal, anterior, and lateral lumbar interbody fusion (TLIF, ALIF, LLIF) procedures. The trial follows earlier studies involving...
Friday Hope: H. Erinaceus (Lion’s Mane): A Mushroom Which May Help Those Suffering From Long COVID/Spike Disease/Injury
The post reviews pre‑clinical data showing that Hericium erinaceus (Lion’s Mane) suppresses NF‑κB, COX‑2 and iNOS while activating Nrf2, thereby reducing inflammation, oxidative stress and supporting neuronal health. Mouse studies demonstrate improved mitochondrial membrane potential, ATP production and antioxidant enzyme...
FDA Approves First Non‑antipsychotic for Dementia Agitation
⚕️ FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia 🔗https://t.co/cPNtkiSXBs 🌐 #DHPSP #Pharma #Healthcare https://t.co/KsBKc45ekk
AstraZeneca’s Breast Cancer Drug Fails to Earn Backing of FDA Advisory Committee
The FDA’s advisory committee voted against recommending AstraZeneca’s oral SERD camizestrant for HR⁺/HER2‑ metastatic breast cancer patients with an ESR1 mutation, citing concerns over the Phase 3 SERENA‑6 trial design. The study switched patients to camizestrant at the point of mutation...
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
Eli Lilly posted a strong Q1 2026, with revenue up 56% YoY to almost $20 billion, driven by $12.8 billion in GLP‑1 sales from Mounjaro and Zepbound. The FDA also approved Foundayo, the first oral GLP‑1 agonist for obesity that can be taken without...
ARCHIMED to Acquire Esperion Therapeutics in a $1.1 Billion Deal
ARCHIMED has agreed to acquire Esperion Therapeutics for approximately $1.1 billion, offering shareholders $3.16 in cash per share—a 58% premium—and a contingent value right (CVR) that could add up to $100 million based on future sales milestones. The transaction values Esperion at...